Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presentations of the ESMO-Magnitude of Clinical Benefit Scale

Since its launch in 2015 the ESMO-MCBS has been presented on a number of occasions

Webcasts and presentations from ESMO Congresses can be accessed by ESMO members, through OncologyPRO.org and conference attendees, through the ESMO conference platform using their LAST NAME and ESMO ID to login (the number printed on your congress badge).

ESMO Virtual Congress 2021: September 2021

The ESMO-MCBS will be presented during the following sessions at the ESMO Virtual Congress 2021

Tuesday, 21 September 2021


Session Title



15:05 - 16:05

Does my patient really benefit from my treatment? Physician, patient and value perspectives

Michiel Strijbos

Channel 3

16:20 - 17:20

ESMO-MCBS: Can we keep it free from bias?

Elisabeth De Vries
Nathan Cherny

Channel 1


The scale was presented or referenced during the following sessions at the ESMO Virtual Congress 2020

Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO-MCBS

Thursday, 17 September: E-Poster Display Session

Challenges in the development and real-world use of the ESMO-MCBS

Sunday, 20 September: Special Session,  11:15 - 12:15 (Channel 2)
Chair: E. De Vries (Groningen, Netherlands)

ESMO-MCBS: What is new and how are we expanding
Nathan Cherny (Jerusalem, Israel)

How can the ESMO-MCBS contribute to a higher QoL for patients?
Andrew Bottomley (Brussels, Belgium)

Prioritising cancer systemic therapies using the ESMO-MCBS: The Israeli experience
Raya Leibowitz (Tel Aviv, Israel)

Shortcomings in study design: Implementation that can skew the ESMO-MCBS results
Bishal Gyawali (Kingston, Canada)

Q&A and live discussion
All Speakers online Chairs to moderate Q&A

Connecting the dots: The ESMO vision on the value of cancer medicines 

Monday, 21 September 2020; Educational Session,  11:15 - 12:15 (Channel 1) 
Chair: Josep Tabernero (Barcelona, Spain) 

Where everything started: The ESMO MCBS
E.G. Elisabeth De Vries (Groningen, Netherlands) 

Where it was logical to go: The ESMO economic model for cancer medicines
Panagiotis Kanavos (London, United Kindgom)

What we need to bring into the equation: The ESMO ESCAT
Joaquin Mateo (Barcelona, Spain) 

Q&A and live discussion
Josep Tabernero (Barcelona, Spain)

Proffered Paper - Public Policy

Monday, 21 September 2020; 14:25 - 16:05 (Channel 1) 

 1583O - Clinical benefit of cancer drugs approved in Switzerland during the last decade

The scale was presented or referenced during the following sessions at the ESMO Congress 2019 

ESMO-MCBS: What have we learnt and how can we expand?

Saturday, 28 September: Special Session,  14:45-16:15, Salamanca Auditorium (Hall 3)

E. De Vries (Groningen, Netherlands)

Lessons learned from ESMO-MCBS testing of multiple adjuvant breast cancer trials
S. Paluch-Shimon (Jerusalem, Israel)

Lessons learned from ESMO-MCBS testing of multiple adjuvant colon cancer
D. De Groot (Groningen, Netherlands)

Taking toxicity into account in the curative setting
N. I. Cherny (Jerusalem, Israel)

Kazakhstan: A success story of working with WHO and ESMO towards sustainable cancer care
D. Kaidarova (Almaty, Kazakhstan), A. Ilbawi (Geneva, Switzerland)

E. De Vries (Groningen, Netherlands)

Poster Discussion Session - Public policy

Sunday, 29 September, 10:15 - 11:45, Leon Auditorium (Hall 3)

1631PD_PR - Clinical benefit and prices of cancer drugs in the US and Europe

Educational Session, Surviving a cancer diagnosis with a good QoL

Monday, 30 September, 08:30 - 10:00, Santander Auditorium (Hall 3)

The physician’s perspective
J. Nuver (Groningen, Netherlands)

EORTC’s work on survivorship
M. Pe (Brussels, Belgium)

Can value frameworks (such as ESMO-MCBS) contribute to a higher QoL?
A. Bottomley (Brussels, Belgium)

Employment and a cancer diagnosis: How does it work in practice?
I. Lebrocquy (Den Haag, Netherlands)

The patient’s perspective
R. Wilson (Church Stretton, United Kingdom)


Proffered paper session - Public policy

Monday, 30 September, 16:30 - 18:00, Salamanca Auditorium (Hall 3)

1626O - ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?

1627O - Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

1628O - Consistency of ESMO-MCBS scores with drug access recommendations in Catalonia

The scale was presented or referenced during the following sessions at the ESMO Congress 2018

Special Session, ESMO-MCBS in perspective

Friday, 19 October, 14:00 - 15:30, ICM - Room 14c

E. De Vries (Groningen, Netherlands)

Comparative assessment of clinical benefit using the ESMO-MCBS v1.1 and the ASCO Value Frameworks Net Health Benefit Score
N. I. Cherny (Jerusalem, Israel)

ESMO-MCBS v1.1 applied in haematological diseases
B. Kiesewetter-Wiederkehr (Vienna, Austria)

How to help countries priorities their cancer systemic therapies –report from the WHO
A. Ilbawi (Geneva, Switzerland)

E. De Vries (Groningen, Netherlands), N. I. Cherny (Jerusalem, Israel)

Poster Discussion Session - Public health policy

Saturday, 20 October, 09:15 - 10:30, Hall B4 - Room 19

1562PD - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)

1563PD - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval

1564PD - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs

1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores

View the webcast

Proffered paper session - Public health policy

Monday, 22 October, 14:45 - 16:15, Hall B3 - Room 22

1555O_PR - Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe

The scale was presented or referenced during the following sessions at the ESMO Congress 2017:

Poster Discussion Session

Saturday, 9 September, 16:30-17:45,  Tarragona Auditorium

1441PD - Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours

Special Session, Cost value and assessment tools of therapies in modern oncology

Sunday, 10 September,  16:30 - 18:00, Alicante Auditorium

N Cherny (Jerusalem, Israel)

Principles and reflections on cost, value and sustainability of anticancer therapies
I Tannock (Toronto, Canada)

ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS): New version 1.1
N Cherny (Jerusalem, Israel)

Integrating the ESMO-MCBS in ESMO Clinical Practice Guidelines
G Pentheroudakis (Ioannina, Greece)

Implementation of the ESMO-MCBS scale

Discussion and conclusions, led by
E de Vries (Groningen, Netherlands)

Proffered Paper Session

Monday, 11 September, 16:30 - 18:00, Alicante Auditorium

1435O_PR - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs.

1436O_PR - How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS

1437O_PR - Clinical Benefit of Randomized Controlled Trials (RCT) Supporting US Food and Drug Administration (FDA) Conversion from Accelerated to Full Approval

Special Session

Friday 16 December, 14:30-16:00, Summit 2

During ESMO Asia 2016 Special Session, ESMO-MCBS and other scales to grade drugs was presented

View the webcast

The scale was presented or referenced during the following sessions at the ESMO Congress 2016

Poster Display

Saturday, 8 October, 13:00-14:00, Hall E

Abstract 1511P: TKIs in first-line for advanced NSCLC with activating EGFR-mutations: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized controlled trials

Poster Discussion session

Saturday, 8 October, 16:30-17:30, room Helsinki

Abstract: 1365PD Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit?

Special Session

Sunday, 9 October, 14:45-16:15, room Helsinki

Clinical benefit of Cancer Drugs

Special Symposium

Monday, 10 October, 11:00-12:30, room Helsinki

ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing in the magnitude of clinical benefit

Proffered Paper session

Monday, 10 October, 16:30-18:00, room Oslo

Abstract 1364O: The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna

During an ESMO Asia 2015 Special Session, Resource constraints as a barrier to lung cancer management: Developing nations, C. Zielinski presented the ESMO Magnitude of Clinical Benefit Scale.

September 2015

Elisabeth de Vries

Elisabeth de Vries presenting the ESMO Magnitude of Clinical Benefit Scale during the ESMO Society session at ECC 2015

The scale was presented at the ESMO Society Session (28 September) during the European Cancer Congress 2015 in Vienna, Austria. E.G. de Vries, Netherlands, presented the scale and A. Eniu, Romania explained how the scale is applied using the data from the ESMO Anti-Neoplastic Medicines Surveys.

Watch E. G. de Vries's presentation

Watch A. Eniu’s presentation

In addition, aspects of the ESMO-MCBS were highlighted and discussed during three further sessions at ECC 2015:

  • ESO Society Session: ‘Is innovation Affordable?’, 26 September: The ESMO initiative on affordable drugs, Speaker: M. Piccart (Belgium)
  • Oncopolicy Forum: Inequalities in Treatment Outcomes, 27 September: The Value of anticancer treatment, Speaker: E. G. de Vries (Netherlands)
  • Special Session: Evaluating Clinical Benefit of Cancer Drugs Across Tumours, 28 September: Chair: E.G. de Vries (Netherlands); Clinical Benefit scale: The European proposal, Speaker: M. Piccart (Belgium); Clinical Benefit scale: The challenge of fairness, Speaker: U. Dafni (Greece)

Webcasts of the above presentations can be accessed via the ECC 2015 website. Select 'webcasts' from the top menu.

May 2015

ESMO-MCBS presented at the ESMO/ASCO Joint Session (30 May) during ASCO 2015, Chicago

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings